HALO - HALOZYME THERAPEUTICS, INC.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 38.57

Open

$ 38.46

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 38.46 - $ 39.01

52 Week Range

$ 29.85 - $ 45.00

Volume

547,134

Average Volume

Market Cap

5.18B

Beta (5Y Monthly)

$ 1.04

PE Ratio (TTM)

$ 18.38

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-20-2024	12-31-2023	10-K
2	11-06-2023	09-30-2023	10-Q
3	08-08-2023	06-30-2023	10-Q
4	05-09-2023	03-31-2023	10-Q
5	02-21-2023	12-31-2022	10-K
6	11-08-2022	09-30-2022	10-Q
7	08-09-2022	06-30-2022	10-Q
8	05-10-2022	03-31-2022	10-Q
9	02-22-2022	12-31-2021	10-K
10	11-02-2021	09-30-2021	10-Q
11	08-09-2021	06-30-2021	10-Q
12	05-10-2021	03-31-2021	10-Q
13	02-23-2021	12-31-2020	10-K
14	11-02-2020	09-30-2020	10-Q
15	08-10-2020	06-30-2020	10-Q
16	05-11-2020	03-31-2020	10-Q
17	02-24-2020	12-31-2019	10-K
18	11-12-2019	09-30-2019	10-Q
19	08-06-2019	06-30-2019	10-Q
20	05-07-2019	03-31-2019	10-Q
21	02-21-2019	12-31-2018	10-K
22	11-06-2018	09-30-2018	10-Q
23	08-07-2018	06-30-2018	10-Q
24	05-10-2018	03-31-2018	10-Q
25	02-20-2018	12-31-2017	10-K
26	11-07-2017	09-30-2017	10-Q
27	08-08-2017	06-30-2017	10-Q
28	05-09-2017	03-31-2017	10-Q
29	02-28-2017	12-31-2016	10-K
30	11-07-2016	09-30-2016	10-Q
31	08-09-2016	06-30-2016	10-Q
32	05-09-2016	03-31-2016	10-Q
33	02-29-2016	12-31-2015	10-K
34	11-09-2015	09-30-2015	10-Q
35	08-10-2015	06-30-2015	10-Q
36	05-11-2015	03-31-2015	10-Q
37	03-02-2015	12-31-2014	10-K
38	11-10-2014	09-30-2014	10-Q
39	08-11-2014	06-30-2014	10-Q
40	05-12-2014	03-31-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on Halo...
04/17/2024 15:41:14

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...

9 Analysts Have This To Say About Halozyme...
04/16/2024 14:01:08

Benchmark Reiterates Buy on Halozyme Thera...
04/16/2024 13:27:28

Benchmark analyst Robert Wasserman reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 price target.

why-biophytis-shares-are-trading-higher-by-around-55-here-are-20-stocks-moving-premarket

Why Biophytis Shares Are Trading Higher By...
04/09/2024 10:05:24

Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.

TD Cowen Initiates Coverage On Halozyme Th...
02/29/2024 11:59:55

TD Cowen analyst Brendan Smith initiates coverage on Halozyme Therapeutics (NASDAQ:HALO) with a Outperform rating and announ...

JMP Securities Reiterates Market Outperfor...
02/21/2024 17:11:11

JMP Securities analyst Jason Butler reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and maintains $7...

Breaking Down Halozyme Therapeutics: 7 Ana...
02/21/2024 12:00:45

HC Wainwright & Co. Maintains Buy on Haloz...
02/21/2024 11:45:53

HC Wainwright & Co. analyst Mitchell Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the pric...

Halozyme Therapeutics Sees FY24 Adj. EPS $...
02/20/2024 21:40:23

Halozyme Therapeutics: Q4 Earnings Insights
02/20/2024 21:05:15

Halozyme Therapeutics Q4 Adj EPS $0.82 Mis...
02/20/2024 21:03:05

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.82 per share which missed the analyst consensus estimate ...

Earnings Scheduled For February 20, 2024
02/20/2024 11:52:12

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue...

Earnings Preview: Halozyme Therapeutics
02/19/2024 16:01:26

bristol-myers-lead-cancer-drug-opdivo-formulated-as-under-skin-injection-at-par-with-intravenous-infusion-in-kidney-cancer-patients

Bristol Myers' Lead Cancer Drug Opdivo For...
01/29/2024 12:43:34

Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell...

Benchmark Reiterates Buy on Halozyme Thera...
01/19/2024 16:52:56

Benchmark analyst Robert Wasserman reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 price target.

HC Wainwright & Co. Reiterates Buy on Halo...
01/19/2024 11:37:06

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $48 ...

halozymes-ambitious-five-year-plan-analysts-optimistic-on-growth-eyeing-market-expansion

Halozyme's Ambitious Five-Year Plan: Analy...
01/18/2024 18:28:55

Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, an...

Expert Outlook: Halozyme Therapeutics Thro...
01/18/2024 17:00:22

JMP Securities Reiterates Market Outperfor...
01/18/2024 16:39:03

JMP Securities analyst Jason Butler reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and maintains $7...

Goldman Sachs Maintains Neutral on Halozym...
01/18/2024 13:49:58

Goldman Sachs analyst Graig Suvannavejh maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and lowers the price ta...